Filing Flows › Cytokinetics (CYTK) › Q2 2026 › vs Q1 2026
Cytokinetics (CYTK) Q2 2026 vs Q1 2026 (quarter over quarter)
Cytokinetics's revenue rose $9.3M (+48%) from $19.4M in Q1 2026 to $28.6M in Q2 2026. The biggest changes: Net Product Revenue +$20.5M (+429%); Collaboration Revenues +$653K (+25%).
Cytokinetics, Q2 2026: revenue $28.6M (-57% year over year), operating margin -626.0%, net loss $199M, operating cash flow −$160M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Net Product Revenue | $25.3M | $4.8M | $20.5M | +429% |
| Collaboration Revenues | $3.3M | $2.6M | $653K | +25% |
| Revenue | $28.6M | $19.4M | $9.3M | +48% |
| Net loss | $199M | $206M | −$7.3M | -4% |
| Costs & expenses | $227M | $225M | $2.0M | +0.9% |
| Operating costs | $208M | $203M | $4.8M | +2% |
| Interest & other, net | $19.6M | $22.4M | −$2.8M | -13% |
| Research & development | $97.8M | $95.5M | $2.3M | +2% |
| SG&A | $104M | $105M | −$499K | -0.5% |
| Other operating costs | $5.6M | $2.6M | $3.0M | +119% |
| Operating cash sources | $199M | $179M | $20.0M | +11% |
| Depreciation & amortization | $3.6M | $3.4M | $253K | +7% |
| Share-based compensation | $35.7M | $30.4M | $5.3M | +17% |
| Cash used in operations | $160M | $145M | $14.4M | +10% |
| Net loss absorbed | $199M | $206M | −$7.3M | -4% |
| Working capital & other | $420K | −$26.8M | $27.2M | — |
Questions
How much did Cytokinetics's revenue grow quarter over quarter in Q2 2026?
Cytokinetics's revenue rose $9.3M (+48%) from $19.4M in Q1 2026 to $28.6M in Q2 2026.
What drove Cytokinetics's revenue change in Q2 2026?
Net Product Revenue +$20.5M (+429%); Collaboration Revenues +$653K (+25%).